Related Experiment Video
Updated: Jun 7, 2026
Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Controversies surrounding iron chelation therapy for MDS
1Division of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. hleitch@providencehematology.com
Abstract:
The myelodysplastic syndromes (MDS) are characterized by cytopenias and acute myeloid leukemia risk. Most MDS patients eventually require transfusion of red blood cells for anemia, placing them at risk of iron overload (IOL). In beta-thalassemia major, transfusional IOL leads to organ dysfunction and death, however, with iron chelation therapy survival improved to near normal and organ function was improved. In lower risk MDS, several non-randomized studies suggest an adverse effect of IOL on survival, and that lowering iron minimizes this impact and may improve organ function. While guidelines for MDS generally recommend chelation in selected lower risk patients, data are emerging suggesting IOL may impact adversely on the outcome of higher risk MDS and stem cell transplantation (SCT) and that lowering iron may be beneficial in these patients. Trials to determine whether these effects are truly from lowering iron are currently enrolling. Chelation is costly and potentially toxic, and in MDS should be initiated after weighing potential risks and benefits for each patient until more definitive data are available. In this paper, data on the impact of IOL in MDS and SCT, possible mechanisms of iron toxicity such as oxidative stress, and the impact of lowering iron on organ function and survival are reviewed.
Insights
Iron overload (IOL) in myelodysplastic syndromes (MDS) may worsen outcomes. Lowering iron through chelation therapy shows potential benefits for survival and organ function in MDS patients, though risks and costs require careful consideration.
Area of Science:
- Hematology
- Oncology
- Transfusion Medicine
Background:
- Myelodysplastic syndromes (MDS) often lead to anemia requiring red blood cell transfusions.
- Transfusion-dependent anemia in MDS patients poses a risk of iron overload (IOL).
- IOL is a known complication in other transfusion-dependent anemias like beta-thalassemia major, impacting organ function and survival.
Purpose of the Study:
- To review the impact of IOL in MDS and stem cell transplantation (SCT).
- To discuss potential mechanisms of iron toxicity, including oxidative stress.
- To evaluate the effects of iron reduction strategies on organ function and survival in MDS.
Main Methods:
- Review of existing non-randomized studies and emerging data on IOL in MDS.
- Analysis of data concerning the impact of IOL on survival and organ function.
- Examination of the role of iron chelation therapy in managing IOL.
Main Results:
- Non-randomized studies suggest IOL adversely affects survival in lower-risk MDS.
- Emerging data indicate IOL may negatively impact outcomes in higher-risk MDS and SCT.
- Iron reduction may improve organ function and survival, but definitive trial data are pending.
Conclusions:
- IOL is a significant concern in MDS, potentially affecting patient outcomes.
- Iron chelation therapy, while beneficial in other conditions, requires careful risk-benefit assessment in MDS due to cost and toxicity.
- Further clinical trials are needed to confirm the benefits of iron reduction in MDS and SCT.
More Related Videos
04:48Setup of Capillary Electrophoresis-Inductively Coupled Plasma Mass Spectrometry (CE-ICP-MS) for Quantification of Iron Redox Species (Fe(II), Fe(III))
Published on: May 4, 2020
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
Related Concept Videos
01:19Complexation Equilibria: The Chelate Effect
01:22EDTA: Chemistry and Properties
01:19Masking and Demasking Agents
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on the metal...
01:26Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:17Antidotes
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
01:14Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...